← Back to Search

Nicotinic Acetylcholine Receptor Agonist

Transdermal Nicotine patch for Depression (DepMIND2 Trial)

Phase 2
Waitlist Available
Led By Warren D Taylor, MD,MHSc
Research Sponsored by Vanderbilt University Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age > 60 years;
Diagnosis of major depressive disorder, single or recurrent episode (DSM5);
Timeline
Screening 3 weeks
Treatment Varies
Follow Up assessed at baseline, week 6, and week 12; only baseline to week 12 reported.
Awards & highlights

DepMIND2 Trial Summary

This trial is testing whether transdermal nicotine enhances cognitive control network (CCN) activity in older adults with Major Depressive Disorder, as measured by fMRI during an emotional response inhibition task.

DepMIND2 Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

DepMIND2 Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~assessed at baseline, week 6, and week 12; only baseline to week 12 reported.
This trial's timeline: 3 weeks for screening, Varies for treatment, and assessed at baseline, week 6, and week 12; only baseline to week 12 reported. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
MADRS (Montgomery Asberg Depression Rating Scale) Score Change
Number of Participants Exhibiting Reduction in Frontal Activation During the Emotional Stroop Task During Functional Magnetic Resonance Imaging (MRI)
Secondary outcome measures
Anxiety Sensitivity Index 3 (ASI-3) Score Change
Apathy Evaluation Scale (AES) Score Change
Attentional Control Scale Score Change
+17 more

Side effects data

From 2022 Phase 2 trial • 29 Patients • NCT04433767
45%
Skin reaction
17%
Headache
17%
Nausea
17%
Dizziness
10%
Increased tension and inner restlessness
10%
Insomnia
10%
Increased dream activity
3%
Fall
100%
80%
60%
40%
20%
0%
Study treatment Arm
Transdermal Nicotine Patch

DepMIND2 Trial Design

1Treatment groups
Experimental Treatment
Group I: Transdermal Nicotine PatchExperimental Treatment1 Intervention
Participants will wear open label transdermal nicotine patch daily for 12-15 weeks. They will apply study patch each morning and remove at bedtime. Dosage will begin at 3.5mg patch / day, increasing to a possible maximum of 21mg patch / day.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Transdermal Nicotine patch
2020
Completed Phase 2
~40

Find a Location

Who is running the clinical trial?

Vanderbilt University Medical CenterLead Sponsor
849 Previous Clinical Trials
669,008 Total Patients Enrolled
17 Trials studying Depression
914 Patients Enrolled for Depression
Warren D Taylor, MD,MHScPrincipal InvestigatorVanderbilt University Medical Center

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
~7 spots leftby Mar 2025